4.6 Article

High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability

Journal

BMC CANCER
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12885-021-07893-7

Keywords

MeSH: breast neoplasms; Chromosomal instability; Tumor suppressor protein p53; Pathology; Other: Targeting Protein for Xenopus Kinesin Like Protein 2 (TPX2)

Categories

Funding

  1. Department of Pathology and Laboratory Medicine at the University of Wisconsin Hospitals and Clinics
  2. University of Wisconsin-Madison Kirschstein National Research Service Award [T32 HL07899]
  3. The Women's 4 Miler Breast Care Fund at the University of Virginia Cancer Center
  4. University of Wisconsin Department of Pathology and Laboratory Medicine
  5. University of Wisconsin Carbone Cancer Center [P30 CA014520]
  6. Office of The Director - National Institutes of Health [S10OD023526]
  7. Cancer Center Support Grant [P30 CA014520]

Ask authors/readers for more resources

TPX2 nuclear expression is strongly associated with high grade morphology, clinical stage, negative ER and PR status, as well as disease-specific and overall survival in breast cancer. Increased TPX2 nuclear expression correlates with elevated ploidy, supernumerary centrosomes, and TP53 mutation. However, TPX2 expression is not an independent predictor of chromosomal instability compared to other clinical and pathologic metrics.
Background: Targeting Protein for Xenopus Kinesin Like Protein 2 (TPX2) is a microtubule associated protein that functions in mitotic spindle assembly. TPX2 also localizes to the nucleus where it functions in DNA damage repair during S-phase. We and others have previously shown that TPX2 RNA levels are strongly associated with chromosomal instability (CIN) in breast and other cancers, and TPX2 RNA levels have been demonstrated to correlate with aggressive behavior and poor clinical outcome across a range of solid malignancies, including breast cancer. Methods: We perform TPX2 IHC on a cohort of 253 primary breast cancers and adopt a clinically amenable scoring system to separate tumors into low, intermediate, or high TPX2 expression. We then correlate TPX2 expression against diverse pathologic parameters and important measures of clinical outcome, including disease-specific and overall survival. We link TPX2 expression to TP53 mutation and evaluate whether TPX2 is an independent predictor of chromosomal instability (CIN). Results: We find that TPX2 nuclear expression strongly correlates with high grade morphology, elevated clinical stage, negative ER and PR status, and both disease-specific and overall survival. We also show that increased TPX2 nuclear expression correlates with elevated ploidy, supernumerary centrosomes, and TP53 mutation. TPX2 nuclear expression correlates with CIN via univariate analyses but is not independently predictive when compared to ploidy, Ki67, TP53 mutational status, centrosome number, and patient age. Conclusions: Our findings demonstrate a strong correlation between TPX2 nuclear expression and aggressive tumor behavior, and show that TPX2 overexpression frequently occurs in the setting of TP53 mutation and elevated ploidy. However, TPX2 expression is not an independent predictor of CIN where it fails to outperform existing clinical and pathologic metrics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available